Skip to main content

Orladeyo

Generic: Berotralstat hydrochloride

Data may be stale·Apr 23, 2026
Manufacturer
BioCryst
NDC
72769-101
RxCUI
2467565
Route
ORAL
ICD-10 indication
D84.1

Affordability Check

How much will you actually pay for Orladeyo?

In 30 seconds, see every legitimate way to afford Orladeyo — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Orladeyo

What is this medication? Orladeyo is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. HAE is a rare genetic disorder characterized by sudden and severe swelling in different parts of the body, such as the hands, feet, face, and throat. This medication is taken orally as a once-daily capsule to help reduce the frequency of these painful and potentially dangerous swelling episodes over time.

The active ingredient in Orladeyo is berotralstat, which belongs to a class of drugs known as plasma kallikrein inhibitors. It works by blocking the activity of an enzyme called plasma kallikrein, which helps control the levels of a protein that triggers swelling. It is important to note that Orladeyo is intended for long-term prevention and should not be used to treat an acute HAE attack that is already occurring.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Orladeyo appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

3%

138 of 5,499 plans

Most common tier

Tier 5

On 83% of covering formularies

Prior authorization required

100%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)2
8%
Tier 2 (generic)1
4%
Tier 5 (specialty)20
83%
Tier 61
4%

Step therapy: 0% of formularies

Quantity limits: 46% of formularies

Coverage breadth: 24 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.

Rare-disease navigation (specialists, trials, patient communities)

Orladeyo treats a rare condition. For in-depth disease pages on our sister site:

UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.